What separates the life sciences CEOs who build enduring companies from those who don’t?

In life sciences, the answer is rarely pedigree, network, or technical knowledge alone. It is the ability to speak two languages simultaneously, the language of science and the language of capital, and to be trusted in both rooms.

Dual Fluency is the practitioner’s guide to mastering that rare combination. Drawing on more than thirty years spanning M&A, licensing, partnering, and capital raises across numerous therapeutic areas, David H. Crean, PhD offers an unfiltered view of how transformative companies get built and sold and why so many promising ones quietly fall apart.

This is not a textbook. It is not a retrospective written from the comfort of retirement. It is the operating thesis of a working professional who has sat on both sides of the table inside large pharma, alongside venture and private equity capital providers, and at the advisory helm of investment banking for some of the sector’s most complex transactions.